Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

AMGN

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

AMGN

AI Research Report

Powered by Claude

Ready to analyze AMGN

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

C+
Stonvex Quant Grade
50.0/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
C+
50 / 100

Today's volume vs prior session average.

Volatility
C+
50 / 100

Absolute daily price move vs peers.

News Flow
C+
50 / 100

24h article count relative to the universe.

Sentiment
C+
50 / 100

AI-classified polarity of recent news.

Dollar Flow
C+
50 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
C+
50 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Biotech →
MRNA
Moderna
$42.80
+5.29%
LLY
Eli Lilly
$810.50
+2.30%
NVO
Novo Nordisk
—
—
BNTX
BioNTech
—
—
REGN
Regeneron
—
—
VRTX
Vertex Pharma
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Amgen Inc

Amgen Inc

Biotechnology·NASDAQ NMS - GLOBAL MARKET·US·IPO 1983-06-17

Analyst Consensus

Buy
Based on 43 analysts
Period: 2026-04-01
21 Buy (49%)19 Hold (44%)3 Sell (7%)
Rating Distribution
Strong Buy
6
Buy
15
Hold
19
Sell
2
Strong Sell
1
Trend
2026-04
21/19/3
2026-03
21/18/3
2026-02
22/16/3
2026-01
22/16/3
📅 Earnings in 16d (Apr 30)
  • Yahoo·1d ago

    Morgan Stanley Raises Amgen (AMGN) Target Ahead of Q1, Truist Lifts Outlook on Pipeline Strength

    Amgen Inc. (NASDAQ:AMGN) is included among the 13 NASDAQ Stocks with Highest Dividends. On April 10, Morgan Stanley analyst Terence Flynn raised the firm’s price recommendation on Amgen Inc. (NASDAQ:AMGN) to $326 from $309. It reiterated an Equal Weight rating on the shares. The firm updated its models across biopharma coverage, reflecting IQVIA trends and […]

  • Yahoo·1d ago

    Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight

    The eosinophilic esophagitis market is witnessing steady growth, primarily driven by the increasing awareness leading to standardized diagnosis and high relapse rates that continue to fuel ongoing treatment demand. Additionally, the expected launch of emerging therapies such as Tezepelumab (TEZSPIRE) (AstraZeneca and Amgen), APT-1011 (fluticasone propionate) (Ellodi Pharmaceuticals), IRL201104 (Revolo Biotherapeutics), Vonoprazan (VOQUEZNA) (Phathom Pharmaceuticals), and others will further prop

  • Yahoo·1d ago

    Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

    The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

  • Yahoo·1d ago

    Beat the Market the Zacks Way: FirstEnergy, Seanergy Maritime, Amgen in Focus

    FirstEnergy gains 10.3% post-upgrade as Zacks highlights standout performers like Seanergy Maritime and Amgen amid a volatile but rising market.

  • Finnhub·1d ago

    Amgen And Shanghai Henlius/Organon Settle Denosumab BPCIA Litigation

    On March 31, 2026, the District Court for the District of New Jersey entered a Consent Order and Judgment in the BPCIA litigation Amgen brought against Henlius and Organon concerning their denosumab...

  • Yahoo·1d ago

    Jim Cramer on Regeneron (REGN): “I Think The Stock’s Breaking Out Here”

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the stocks Jim Cramer discussed alongside the tech market divide. Toward the end of the lightning round, a caller sought Cramer’s thoughts on the company, and here’s what he had to say in response: I think Regeneron, I think Leonard Schleifer’s doing an unbelievable job. I think the stock’s […]

  • Yahoo·3d ago

    Assessing Amgen (AMGN) Valuation As TEPEZZA And MariTide Trial Results Draw Fresh Investor Focus

    Why TEPEZZA and MariTide Are Back in Focus for Amgen (AMGN) Amgen (AMGN) is drawing fresh attention after Phase 3 data for subcutaneous TEPEZZA in Thyroid Eye Disease and strong weight loss results for obesity candidate MariTide reshaped expectations around its specialty and metabolic portfolios. See our latest analysis for Amgen. Amgen’s recent TEPEZZA and MariTide updates arrive during a period of solid momentum, with a 90 day share price return of 7.64% and a 1 year total shareholder...

  • Yahoo·3d ago

    This Startup’s Psoriasis Drug Studies Have Lifted Its Stock

    Phase 1 studies showed that one shot of ORKA-001 lasted long enough to allow dosing twice-a-year—or even once-a-year.

  • View all news →
    • NASDAQ NMS - GLOBAL MARKETAfter-hours
    Amgen Inc
    Biotechnology
    $350.02
    $0.20 (+0.06%)
    After-hrs · vs prev close $349.82
    Open
    $346.71
    Prev close
    $349.82
    Day range
    $345.41 – $351.37
    52W range
    $261.43 – $391.29
    Mkt cap
    $188.58B
    P/E
    24.4
    EPS
    $14.23
    Beta
    0.49

    Fundamentals

    Valuation
    Market Cap
    $188.58B
    P/E (TTM)
    24.45S&P avg ~22
    P/S (TTM)
    5.13S&P avg ~2.8
    P/B
    20.36S&P avg ~4.5
    P/FCF
    23.27S&P avg ~26
    EPS (TTM)
    $14.23
    Book/sh
    $16.06
    Cash/sh
    $16.94
    Profitability
    Gross Margin
    73.30%avg ~45%
    Operating Margin
    25.43%avg ~15%
    Net Margin
    20.98%avg ~12%
    ROE
    96.65%avg ~18%
    ROA
    8.62%avg ~7%
    ROI
    12.11%
    Payout Ratio
    72.03%
    FCF/sh
    —
    Growth & Health
    Rev Growth YoY
    9.95%
    Rev Growth 5Y
    7.65%
    EPS Growth YoY
    88.56%
    EPS Growth 5Y
    2.93%
    Current Ratio
    —
    Quick Ratio
    0.90
    Debt/Equity
    —
    LT Debt/Eq
    —
    Trading & Dividends
    Beta
    0.49
    52W High
    $391.29
    52W Low
    $261.43
    Avg Vol (10D)
    2.64M
    Avg Vol (3M)
    2.83M
    Div Yield
    2.88%
    Div/sh (TTM)
    —
    Analyst
    Buy (43)
    Price Performance
    5D+2.89%
    MTD-0.58%
    3M+5.97%
    6M+18.94%
    YTD+6.88%
    1Y+24.31%

    Factor Grades

    View details →
    B-
    Overall score: 66/100
    C-
    Valuation
    B-
    Growth
    A-
    Profitability
    B
    Momentum
    B
    Financial Health
    ⚠️
    Dilution risk detected

    4 offering-related filings in the last 60 filings. Latest: 424B2 on 2026-02-19. View all →

    Recent insider activity

    View all →
    • 4PRIMARY DOCUMENT
      27d ago
    • 4PRIMARY DOCUMENT
      27d ago
    • 4PRIMARY DOCUMENT
      27d ago
    • 4PRIMARY DOCUMENT
      27d ago
    • 4PRIMARY DOCUMENT
      27d ago